Antitumor activity of a recombinant soluble ectodomain of mutant human fibroblast growth factor receptor-2 IIIc

Molecular Cancer Therapeutics

Volumn 10, Issue 9, 2011, Pages 1656-1666

  Wang, Ju ^a   Liu, Xue Ting ^a   Huang, Hui ^b   Xiao, Gang ^a   Zhou, Zhi You ^a   Chen, Yang ^a   Yu, Zhi Hong ^a   He, Shui Lian ^a   Chen, An An ^a   Wang, Ding Ding ^c   He, Ying ^a   Zhang, Zhi Cheng ^a   Hong, An ^a  

^a JINAN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FIBROBLAST GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MUTANT SOLUBLE ECTODOMAIN FIBROBLAST GROWTH RECEPTOR 2 IIIC; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL VIABILITY; CONTROLLED STUDY; DRUG RECEPTOR BINDING; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; THERMODYNAMICS; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIGANDS; MICE; MICE, INBRED BALB C; MICE, NUDE; MUTANT PROTEINS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PHYSIOLOGIC; NIH 3T3 CELLS; PEPTIDE FRAGMENTS; PROTEIN BINDING; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80052741228     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0163     Document Type: Article

References (39)

1. Burgess WH, Maciag T. The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem 1989;58:575-606. (Pubitemid 19172981)
2. Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005;16:139-49. (Pubitemid 40616112)
3. Dailey L, Ambrosetti D, Mansukhani A, Basilico C. Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev 2005;16:233-47. (Pubitemid 40616120)
4. Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000;7:165-97.
5. Basilico C, Moscatelli D. The FGF family of growth factors and oncogenes. Adv Cancer Res 1992;59:115-65.
6. Yan G, Fukabori Y, McBride G, Nikolaropolous S, McKeehan WL. Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol Cell Biol 1993;13:4513-22. (Pubitemid 23220358)
7. Compagni A, Wilgenbus P, Impagnatiello MA, Cotten M, Christofori G. Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res 2000;60:7163-9. (Pubitemid 32059199)
8. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005;16:159-78. (Pubitemid 40616114)
9. Auguste P, Javerzat S, Bikfalvi A. Regulation of vascular development by fibroblast growth factors. Cell Tissue Res 2003;314:157-66. (Pubitemid 37409921)
10. Cross MJ, Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 2001;22:201-7. (Pubitemid 32244307)
11. Cronauer MV, Schulz WA, Seifert HH, Ackermann R, Burchardt M. Fibroblast growth factors and their receptors in urological cancers: basic research and clinical implications. Eur Urol 2003;43:309-19. (Pubitemid 36314245)
12. Dorkin TJ, Robinson MC, Marsh C, Neal DE, Leung HY. aFGF immunoreactivity in prostate cancer and its co-localization with bFGF and FGF8. J Pathol 1999;189:564-9.
13. Kornmann M, Beger HG, Korc M. Role of fibroblast growth factors and their receptors in pancreatic cancer and chronic pancreatitis. Pancreas 1998;17:169-75. (Pubitemid 28345813)
14. Sliutz G, Tempfer C, Obermair A, Dadak C, Kainz C. Serum evaluation of basic FGF in breast cancer patients. Anticancer Res 1995;15:2675-7. (Pubitemid 26095080)
15. Visscher DW, DeMattia F, Ottosen S, Sarkar FH, Crissman JD. Biologic and clinical significance of basic fibroblast growth factor immunostaining in breast carcinoma. Mod Pathol 1995;8:665-70.
16. Barclay C, Li AW, Geldenhuys L, Baguma-Nibasheka M, Porter GA, Veugelers PJ, et al. Basic fibroblast growth factor (FGF-2) overexpression is a risk factor for esophageal cancer recurrence and reduced survival, which is ameliorated by coexpression of the FGF-2 antisense gene. Clin Cancer Res 2005;11:7683-91. (Pubitemid 41611610)
17. Abate-Shen C, Shen MM. FGF signaling in prostate tumorigenesis - new insights into epithelial-stromal interactions. Cancer Cell 2007;12:495-7. (Pubitemid 350199077)
18. Kwabi-Addo B, Ozen M, Ittmann M. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer 2004;11:709-24. (Pubitemid 40065546)
19. Sahadevan K, Darby S, Leung HY, Mathers ME, Robson CN, Gnanapragasam VJ. Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. J Pathol 2007;213:82-90. (Pubitemid 47354569)
20. Acevedo VD, Ittmann M, Spencer DM. Paths of FGFR-driven tumorigenesis. Cell Cycle 2009;8:580-8.
21. Luqmani YA, Bansal GS, Mortimer C, Buluwela L, Coombes RC. Expression of FGFR2 BEK and K-SAM mRNA variants in normal and malignant human breast. Eur J Cancer 1996;32A:518-24.
22. Jang JH, Shin KH, Park JG. Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res 2001;61:3541-3.
23. Pollock PM, Gartside MG, Dejeza LC, Powell MA, Mallon MA, Davies H, et al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 2007;26:7158-62. (Pubitemid 350059681)
24. Hansen RM, Goriely A, Wall SA, Roberts IS, Wilkie AO. Fibroblast growth factor receptor 2, gain-of-function mutations, and tumourigenesis: investigating a potential link. J Pathol 2005;207:27-31. (Pubitemid 41200711)
25. Mohammadi M, Olsen SK, Ibrahimi OA. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev 2005;16:107-37. (Pubitemid 40616111)
26. Olsen SK, Ibrahimi OA, Raucci A, Zhang F, Eliseenkova AV, Yayon A, et al. Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity. Proc Natl Acad Sci U S A 2004;101:935-40. (Pubitemid 38160562)
27. Ibrahimi OA, Zhang F, Eliseenkova AV, Itoh N, Linhardt RJ, Mohammadi M. Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities. Hum Mol Genet 2004;13:2313-24. (Pubitemid 39359928)
28. Anderson J, Burns HD, Enriquez-Harris P, Wilkie AO, Heath JK. Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand. Hum Mol Genet 1998;7:1475-83. (Pubitemid 28429929)
29. Tassi E, Al-Attar A, Aigner A, Swift MR, McDonnell K, Karavanov A, et al. Enhancement of fibroblast growth factor (FGF) activity by an FGF-binding protein. J Biol Chem 2001;276:40247-53.
30. 1-phase by a common mechanism. Mol Biol Cell 2004;15:801-14.
31. Hanneken A, Ying W, Ling N, Baird A. Identification of soluble forms of the fibroblast growth factor receptor in blood. Proc Natl Acad Sci U S A 1994;91:9170-4.
32. Gowardhan B, Douglas DA, Mathers ME, McKie AB, McCracken SR, Robson CN, et al. Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer. Br J Cancer 2005;92:320-7. (Pubitemid 40343148)
33. Ogawa T, Takayama K, Takakura N, Kitano S, Ueno H. Anti-tumor angiogenesis therapy using soluble receptors: enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor. Cancer Gene Ther 2002;9:633-40. (Pubitemid 34847570)
34. Gowardhan B, West AF, Robson CN, Leung HY. Adenovirus-mediated expression of a soluble fibroblast growth factor receptor inhibits in vitro growth of prostate DU145 cells. Prostate 2004;61:50-9. (Pubitemid 39095694)
35. Patel RR, Sengupta S, Kim HR, Klein-Szanto AJ, Pyle JR, Zhu F, et al. Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors. Eur J Cancer 2010;46:1537-53.
36. Suyama K, Shapiro I, Guttman M, Hazan RB. A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor. Cancer Cell 2002;2:301-14. (Pubitemid 41043964)
37. Xian W, Schwertfeger KL, Rosen JM. Distinct roles of fibroblast growth factor receptor 1 and 2 in regulating cell survival and epithelial-mesenchymal transition. Mol Endocrinol 2007;21:987-1000. (Pubitemid 46984736)
38. Acevedo VD, Gangula RD, Freeman KW, Li R, Zhang Y, Wang F, et al. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell 2007;12:559-71. (Pubitemid 350199071)
39. Chaffer CL, Brennan JP, Slavin JL, Blick T, Thompson EW, Williams ED. Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res 2006;66:11271-8. (Pubitemid 46009956)